NATTOPHARMA: RE-ELECTION OF CHAIRMAN, AND ELECTION OF TWO NEW BOARD MEMBERS

Frode Marc Bohan was re-elected as Chairman of the Board of Directors for
NattoPharma ASA at the company’s Annual General Meeting, held Friday 20th May,
2016. Frode Marc Bohan is re-elected for a period of two years, up until the
ordinary Annual General Meeting in 2018.
The Annual General Meeting further resolved to increase the Board of Directors
from 3 to 5 members. Stefan Halldén and Annette Emlqvist were elected for a two
-year period, until the ordinary Annual General Meeting in 2018.

Stefan Halldén (50) is today working chairman of Life Science Sweden AB, a long
time shareholder in NattoPharma and a valuable contributor to the development of
the company. The last year he also held the position as a member of the Election
Committee. Halldén has a long track record from international finance.

Anette Elmqvist (67) has an extensive operational experience from various health
and pharma companies as Swedish Pharmacies, KabiVitrum AB, Pharmacia
Biopharmaceuticals AB, Pharmacia & Upjohn AB, Active Biotech AB, PowderJect SBL
Vaccin AB, SBL Vaccin AB and Unitech Biopharma AB. Today Elmqvist serve as VP
Quality Assurance in Scandinavian Biopharma AB.

“The election of Stefan Halldén and Annette Elmqvist as members of the Board of
Directors in NattoPharma ASA is continuing the efforts to move NattoPharma from
an “entrepreneurial start-up company” within the dietary supplement business
segment to a visible player within global biotechnology, nutraceutical and the
pharmaceutical field. Annette Elmqvist extensive operational and pharmaceutical
production experience will be a great asset for NattoPharma.  Combined with
Stefan Halldén extensive financial background, I believe that the extended board
will contribute greatly to the success of NattoPharma ASA” says Frode M. Bohan,
Chairman of the Board in NattoPharma

For more information, please contact:

Kjetil Ramsøy

CFO, NattoPharma

E-mail: kjetil.ramsoy@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the world's leader in vitamin K2 R&D.
NattoPharma is the exclusive international supplier of MenaQ7® Vitamin K2 as MK
-7, the best documented, commercially available Vitamin K2 as MK-7 with
guaranteed actives and stability, clinical substantiation, and international
patents granted and pending. The company has a multi-year research and
development program to substantiate and discover the health benefits of vitamin
K2 for applications in the marketplace for functional food and dietary
supplements. With a global presence, the company established its North American
subsidiary, NattoPharma USA, Inc., in Metuchen, NJ.

For more information, visit www.nattopharma.com or www.Menaq7.com